Clinical trials: Digestive Infection
Hiv, Syphilis
MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia
Elimination of mother-to-child-transmission (EMTCT) of HIV, syphilis and hepatitis B are key priorities in Indonesia, the fourth most populous country in the world.
- Conditions
- Hiv, Syphilis, Hepatitis B
- Trial name
- MENJAGA (NCT06058286)
- Testing
- Continuous quality improvement
- Where
- Indonesia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Yanri Wijayanti Subronto, MD, PhD,
Hepatitis B
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults
This study is undertaken to assess the immune response and safety profile of 4 lots of the novel adjuvanted hepatitis B vaccine that were formulated following different processes, with Engerix™-B as the control vaccine
- Trial name
- NCT00697853
- Testing
- Engerix™-B, HBV-MPL vaccine 208129
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and…
- Trial name
- NCT01038167
- Testing
- telaprevir, cyclosporine, tacrolimus
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Esophageal Cancer, Microbial Colonization
The Microbiome of Oesophageal Squamous Cell Carcinoma
This is a prospective study on the microbiota associated with oesophageal squamous cell carcinoma (SCC). Patients with newly diagnosed SCC of oesophagus would be recruited for taking samples of oral and oesophageal rinse, tissue…
- Trial name
- NCT04425122
- Testing
- Upper endoscopy
- Where
- Hong Kong
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
Background: Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States.
- Conditions
- Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic
- Trial name
- NCT00913757
- Where
- 2 sites in United States
- Volunteers
- 1,871 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Tuberculosis, Drug Induced Liver Injury
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
- Conditions
- Tuberculosis, Drug Induced Liver Injury, Hepatitis
- Trial name
- NCT05738681
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Postoperative Sore Throat
Effect of Colding of Endotracheal Tubes on Sore Throat
Postoperative sore throat (POST) is a common and undesirable postoperative symptom that causes patient dissatisfaction. Cold application is a non-invasive, non-pharmacological, cost-effective and effort-effective therapy for pain…
- Trial name
- NCT05834179
- Testing
- cold endotracheal tube
- Where
- Turkey (Türkiye)
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Baskent University
HEPATITIS C (HCV)
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
The metabolism of PF-00868554 is primarily mediated by CYP3A, and it is anticipated that hepatic impairment will modify PF-00868554 plasma concentrations.
- Trial name
- NCT00651027
- Testing
- PF-868554
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Chronic Hepatitis B
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931.
- Trial name
- NCT03038113
- Testing
- RO7062931, Immune Modulator
- Where
- 19 sites in Australia, Hong Kong and 5 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers
The purpose of this study is to evaluate the drug-drug interaction between steady-state concentrations of CYP3A4 or ritonavir and TMC435350 after its first and the last dose of the multiple dosing regimen and to explore the short…
- Trial name
- NCT01891851
- Testing
- TMC435350 200 mg, Ritonavir 100 mg
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)
This study will compare the pharmacokinetics (PK) of grazoprevir (MK-5172) when administered to participants with mild, moderate or severe hepatic insufficiency (assessed by the criteria of the Child-Pugh's scale) with the PK of…
- Trial name
- NCT01390428
- Testing
- Grazoprevir
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Shigellosis
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain…
- Trial name
- S4V03 (NCT06615375)
- Testing
- Shigella4V2
- Where
- 3 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Chronic Hepatitis C
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects
- Trial name
- HEC110114 (NCT03903081)
- Testing
- HEC110114 tablet
- Where
- China
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Infections, Meningococcal
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
The purpose of this study is to assess the safety and reactogenicity of a booster dose of diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) at 15-18 m and to assess the…
- Trial name
- NCT00317109
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACW
- Where
- 3 sites in South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Diphtheria
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar…
- Conditions
- Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT02096263
- Testing
- Infanrix hexa, Pediarix, ActHIB
- Where
- 43 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cholera
Immunity to Human Cholera in Bangladesh
Cholera is a severe diarrhea illness caused by bacteria. The purpose of this study is to better understand how the immune systems of people in Dhaka, Bangladesh, fight infection with cholera.
- Trial name
- NCT00401934
- Where
- Bangladesh
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy
The main purpose of this study is to evaluate the safety and tolerability of combination therapy of daily interferon alfacon-1 (Infergen, CIFN) at high dosage (24 mcg) with ribavirin (based on body weight) for 48 weeks in HCV…
- Trial name
- NCT00266318
- Testing
- Interferon Alfacon-1 and Ribavirin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center
Hepatitis B
Characterisation of Human B Cell Maturation in Response to Vaccination
This study is an exploratory single site sample collection study at St Mary's hospital campus, Imperial College London. Sixteen participants scheduled to receive routine immunizations for Td/IPV (group 1) and HBsAg (group 2) will…
- Trial name
- BVAC (NCT03535779)
- Testing
- Hepatitis B, Tetanus Toxoid
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis B
A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA
Primary objective: To describe in subjects vaccinated with 3 doses of HEXAVAC® or 3 doses of INFANRIX®-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre ≥10 mIU/mL 1 month after a…
- Trial name
- NCT00693186
- Testing
- HBVaxPRO® 5 µg / 0.5 mL, Engerix B® 10 µg / 0.5 mL
- Where
- 5 sites in Italy
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.